The Name Over the Counter: Who Owns Your Pharmacy, and Who Decides Which Ones Stay Open

Pharmacies weren't rolled up by private equity the way vet clinics and dental offices were. The bigger force is three companies that manage prescription benefits for most Americans, and that also own insurers and pharmacies. How that works, why nearly a third of the pharmacies operating since 2010 had closed by 2021 even as others opened, what happened when Rite Aid shut down, and what Washington and the states have done about it.

The short version

Nearly a third of the retail pharmacies that operated in the U.S. from 2010 to 2020 had closed by 2021, more often in predominantly Black and Latino neighborhoods than in white ones, though new pharmacies opened too. Rite Aid, once the third-largest drugstore chain, closed its last stores in 2025, and Walgreens was bought by the private equity firm Sycamore Partners the same year. Part of the backdrop is a corner of the system most customers never see. Three pharmacy benefit managers, companies hired by insurers and employers to run their drug coverage, handled nearly 80% of American prescriptions in 2023, and each belongs to a company that also owns a big insurer and its own pharmacies. Independent pharmacists and the FTC's staff say that can let them pay rival pharmacies less and steer patients to their own; the benefit managers say they hold down drug costs and that closures have other causes, and a federal inspector general's study found mixed effects. In 2026 the FTC reached insulin-pricing settlements with two of the three, and Congress changed how they're paid in Medicare. Arkansas tried to ban them from owning pharmacies, and a court has blocked the law.

New articles and charts arrive in one short email on Monday mornings. Get the weekly digest

The analogy

A town's only wholesale market is run by the same company that owns the biggest grocery chain in town. The market decides what every independent grocer is reimbursed when a customer pays with the town's food vouchers, and it can encourage voucher holders to shop at its own stores. The chain's stores may well be efficient. The question is whether the market's terms leave the independents a fair chance.

The market is the pharmacy benefit manager. The chain is the pharmacies it owns.

Figures below are as of early November 2026.

How many pharmacies there are

How you count changes the answer, and the two sides cite different counts.

Share of pharmacies operating in 2010–2020 that had closed by 2021

Neighborhoods by the group that makes up most of their residents. Source: Guadamuz et al., Health Affairs, 2024

About one in eight U.S. neighborhoods lacks convenient access to a pharmacy, by researchers' definition: none within a mile in cities, two miles in suburbs, ten miles in rural areas, or half a mile in low-income neighborhoods where few households have cars (University of Southern California).

Who fills America's prescriptions

Americans' prescriptions brought in $751 billion in dispensing revenue in 2025. The largest pharmacy companies by that revenue were CVS, about $119 billion; Walgreens, about $91 billion; Cigna's Express Scripts, through its mail and specialty pharmacies, about $81 billion; UnitedHealth's Optum Rx, about $50 billion; and Walmart, about $37 billion. The top four had more than half (Drug Channels, an industry analyst; Becker's Hospital Review). From 2010 to 2025 CVS and Walgreens announced acquisitions of more than 6,000 pharmacy locations (Drug Channels).

The chains in trouble

Rite Aid, then the nation's third-largest drugstore chain (Axios), filed for bankruptcy in October 2023, closed about 500 stores and emerged in September 2024 (CNN), then filed again in May 2025 with about 1,240 stores (NJBIZ). A court approved the sale of its prescription files to CVS, Walgreens, Albertsons, Kroger and others (Reuters), and its last stores closed in October 2025. It had carried more than $4 billion in debt, partly from lawsuits over opioids (WPVI); Healthcare Dive also pointed to flat reimbursement, labor costs, weak front-of-store sales and online competition (Healthcare Dive).

Walgreens was taken private by Sycamore Partners in August 2025 (Sycamore Partners), in a deal Walgreens said could be worth up to $23.7 billion including debt and possible future payouts, and split into five separate companies (Fierce Healthcare).

CVS announced about 900 closures for 2022 through 2024 (Reuters); in 2025 it opened 87 locations and closed 243 (CVS Health, 2025 annual report).

The middlemen

Pharmacy benefit managers negotiate with drugmakers for rebates, decide which drugs a plan covers, and set what pharmacies are paid for each prescription. The FTC's staff found that the three largest, CVS Caremark, Cigna's Express Scripts and UnitedHealth's Optum Rx, processed nearly 80% of the roughly 6.6 billion prescriptions filled in 2023, and the six largest more than 90%. All six operate their own mail-order and specialty pharmacies, and the largest are part of companies that include the nation's largest health insurers (FTC, July 2024; report).

What the FTC's staff found. In two interim reports, the staff said the three largest benefit managers' own pharmacies' share of specialty-drug dispensing revenue grew from 54% in 2016 to 68% in 2023, and that on 51 specialty generic drugs their affiliated pharmacies took in more than $7.3 billion above the drugs' estimated acquisition cost from 2017 to 2022, with signs that the benefit managers may be steering patients to them (FTC, July 2024; FTC, January 2025). The commissioners split over the first report: Melissa Holyoak dissented, saying it failed "to meet the standards of economic rigor," and Andrew Ferguson, now chairman, said the agency needed to learn whether these practices "ultimately affect consumers' out-of-pocket costs" (Holyoak; Ferguson).

A federal audit. In May 2026 the inspector general of the Department of Health and Human Services compared Medicare drug plans run by companies that also own benefit managers and pharmacies with other plans. Net drug costs were similar, within 1%; the integrated companies paid their own pharmacies a little less than others did; and their enrollees paid lower premiums but substantially higher out-of-pocket costs. The inspector general said the full effects of integration remain unknown (HHS Office of Inspector General).

The insulin case. In 2024 the FTC sued the three over insulin pricing. Express Scripts settled in February 2026, and Caremark agreed to a proposed settlement in July 2026; the terms include fees not tied to drugs' list prices, patients' costs based on the price after rebates, and an option for community pharmacies to be paid their cost plus a fee (FTC). The case against Optum Rx was withdrawn from the FTC's court in June 2026 to consider a settlement (Healthcare Dive).

Congress. A spending law signed in February 2026 requires that, from 2028, benefit managers in Medicare's drug program be paid flat fees not tied to drug prices; opens Medicare drug plans' networks to any willing pharmacy from 2029; and requires that rebates pass through to employer health plans. It didn't include a broad ban on spread pricing, the practice of charging a plan more for a drug than the benefit manager pays the pharmacy and keeping the difference (Sidley Austin; Hall Render; Managed Healthcare Executive).

The states

Arkansas passed a law in 2025 barring benefit managers from owning pharmacies in the state. Express Scripts, CVS, Optum and their trade group sued, and in July 2025 a federal judge blocked it, finding it likely violates the Constitution's limits on state laws that burden interstate commerce and, for Express Scripts, is likely overridden by federal military health-coverage law. The appeals court heard arguments on September 22, 2026, and hasn't ruled (NCPA; docket). Tennessee passed a law in May 2026 limiting common ownership of pharmacies with insurers or benefit managers from July 2028 (Mintz); Caremark, Express Scripts and their trade group have sued (Applied Policy).

California took a different route. A 2025 law bars spread pricing in contracts signed or renewed from 2026 and voids remaining clauses in 2029, requires rebates to pass through to plans, and bars steering patients to benefit managers' own pharmacies; a separate 2025 budget law has the state license benefit managers from 2027. Neither bars them from owning pharmacies (Office of the Governor; bill text). Optum Rx sued in May 2026 to block parts of the law (Mintz).

What closures do

A 2019 study of 3.1 million older Americans found that after their pharmacy closed, adherence to statins, beta blockers and blood thinners, measured as the share of days patients had their medicine on hand, fell about six percentage points and stayed lower for a year, with larger drops for people who had used independent pharmacies or lived in areas with fewer pharmacies (Qato et al., JAMA Network Open). The study shows an association, not proof that the closures caused the drop.

Where the analogy breaks

A town's grocers can at least see the wholesale prices. Pharmacy benefit managers' contracts, rebates and payments to pharmacies are mostly confidential, which is part of why the FTC had to compel data to study them. And customers rarely choose their benefit manager; their employer or insurer does.

What people argue about

The middlemen. The benefit managers' trade group says the market is "extremely competitive" and called the FTC's first report "anecdotes" and "two cherry-picked case studies" (PCMA). It says benefit managers pass through well over 95% of rebates (PCMA), and it cites an analysis by the economist Dennis Carlton, paid for by the three largest benefit managers, which found independents are paid 4% more for brand drugs and 24% more for generics than unaffiliated chains (Compass Lexecon). The independents' association says benefit managers pay below cost, claw back payments after the fact and steer patients to pharmacies they own (NCPA).

Why pharmacies close. The closure study's authors say the declines are consistent with chain mergers and the joining of benefit managers with chains, and that such integration may contribute to low reimbursement (Health Affairs). The benefit managers point to online shopping, rural population loss and pharmacist burnout (PCMA); Rite Aid's collapse has been tied to reimbursement, costs and debt (Healthcare Dive; WPVI).

Ownership. Arkansas and Tennessee chose to separate benefit managers from pharmacies; California chose to regulate their conduct instead; in 2025, 39 attorneys general urged Congress to adopt similar restrictions nationally (Arizona Capitol Times). The benefit managers argue that their mail-order and specialty pharmacies save money, mail order by an estimated $23.5 billion over ten years and specialty pharmacies by up to 45% on some drugs (PCMA), and warn that ownership bans could cause pharmacy closures. The courts will decide how far states can go.

See also

Sources

The weekly digest

One email on Monday mornings: the week's new articles and charts, the numbers that moved most, and what comes out in the week ahead. No ads, and no tracking of opens or clicks.

Past issuesHow addresses are kept